With elucidation of the oncogenic mechanisms of RCC, however, agents that target critical molecules in the biological pathways necessary for oncogenesis, such as vascular endothelial cell growth factor or the mammalian target of rapamycin (mTOR), have been developed. The gene discussed is MTOR; the disease is renal cell carcinoma.